Insulin Pharma Companies Regulation 
pharmaphorum
JUNE 14, 2021
Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. This article appears in our free digital magazine Deep Dive: Market Access 2021.
Pharmaceutical Technology
JANUARY 31, 2023
FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. That leaves three years for pharma companies to prepare. It’s much needed. It’s a hot area.” trillion Consolidated Appropriations Act.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MAY 21, 2021
Based in Cambridge, Arecor has proprietary formulation technology and plans to enter development partnerships and licence out drugs to big pharma companies, looking for milestone payments and royalties as they progress through the development process and on commercialisation.
pharmaphorum
JUNE 2, 2022
This is why the action by the US in 1983 and subsequently the European Commission Regulation No. 141/2000 (the Orphan Regulation), that both acted to encourage development in the area, are regarded as crucial for changing the landscape in rare disease R&D. It is estimated that between 3.5 The price is right. Reaching a compromise.
The Pharma Data
MAY 14, 2021
First, most are on the payroll of the big pharma companies earning lucrative commissions for pushing their drugs…. Yes, it’s important to get rid of unproductive carbohydrates, refined sugars and processed foods… …If you don’t you’ll suffer more insulin resistance and unstable blood readings.
Delveinsight
AUGUST 25, 2021
Pharmaceutical companies may deal in both generic and brand-name drugs as well as medical devices. They are governed by a number of rules and regulations that govern drug patenting, testing, safety, efficacy, and marketing. . The global healthcare spending in 2020 was USD 8.3 trillion and it is expected to increase to USD 8.8
pharmaphorum
JUNE 10, 2021
The fundamental misconception among the public, the media and even some lawmakers is that higher drug list prices are the result of drug manufacturers being in a monopolistic position to endlessly raise prices on critical drugs like insulin and then rake in big profits. What’s Next: How Should Pharma Companies Respond?
Expert insights. Personalized for you.
98 
Let's personalize your content